US2019269637A1PendingUtilityA1
Alkylamido Compounds and Uses Thereof
Est. expiryFeb 16, 2029(~2.6 yrs left)· nominal 20-yr term from priority
A61K 2800/78A61K 31/196C07D 319/08A61Q 19/02C07C 233/54A61Q 5/00C07C 235/38C07D 307/79A61Q 19/06A61Q 19/08A61K 2121/00A61K 8/42A61Q 7/00A61Q 7/02
75
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed herein are compounds that may be specific to PPAR and/or EGF receptors, and methods of making and using same.
Claims
exact text as granted — not AI-modified1 - 19 . (canceled)
20 . The compound N-acetyl-(S)-3-(4-aminophenyl)-2-methoxypropionic acid, or a pharmaceutically acceptable salt or an N-oxide thereof.
21 . A pharmaceutical composition comprising the compound of claim 20 , or a pharmaceutically acceptable salt or an N-oxide thereof; and a pharmaceutically acceptable carrier.
22 . The compound N-acetyl-(S)-3-(4-aminophenyl)-2-methoxypropionic acid, or a pharmaceutically acceptable salt thereof.
23 . A pharmaceutical composition comprising the compound of claim 22 , or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
24 . The compound N-acetyl-(S)-3-(4-aminophenyl)-2-methoxypropionic acid.
25 . A pharmaceutical composition comprising the compound of claim 24 ; and a pharmaceutically acceptable carrier.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.